Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment

Nicotinamide adenine dinucleotide (NAD) is the core of cellular energy metabolism. NAMPT, Sirtuins, PARP, CD38, and other molecules in this classic metabolic pathway affect many key cellular functions and are closely related to the occurrence and development of many diseases. In recent years, severa...

Full description

Saved in:
Bibliographic Details
Published inCancer cell international Vol. 22; no. 1; pp. 1 - 21
Main Authors Xu, QinChen, Liu, Xiaoyan, Mohseni, Ghazal, Hao, Xiaodong, Ren, Yidan, Xu, Yiwei, Gao, Huiru, Wang, Qin, Wang, Yunshan
Format Journal Article
LanguageEnglish
Published London BioMed Central 30.07.2022
BMC
Subjects
Adenosine
Angiogenesis
Antigens
Apoptosis
Breast cancer
CD38 antigen
Cell growth
Chemokines
Cytokines
Cytotoxicity
Drug delivery
Drug development
Drug discovery
Drug resistance
Energy metabolism
Enzymes
Hypoxia
Immunosuppressive agents
Immunotherapy
Ligands
Lymphocytes
Metabolic pathways
Metabolism
Metastasis
Microenvironments
NAD
NAD + metabolism
Neoantigens
Neutrophils
Review
Sirtuins
Tumor immune microenvironment
Tumor necrosis factor-TNF
Tumor therapy
Tumors
Online AccessGet full text

Cover

Abstract Nicotinamide adenine dinucleotide (NAD) is the core of cellular energy metabolism. NAMPT, Sirtuins, PARP, CD38, and other molecules in this classic metabolic pathway affect many key cellular functions and are closely related to the occurrence and development of many diseases. In recent years, several studies have found that these molecules can regulate cell energy metabolism, promote the release of related cytokines, induce the expression of neoantigens, change the tumor immune microenvironment (TIME), and then play an anticancer role. Drugs targeting these molecules are under development or approved for clinical use. Although there are some side effects and drug resistance, the discovery of novel drugs, the development of combination therapies, and the application of new technologies provide solutions to these challenges and improve efficacy. This review presents the mechanisms of action of NAD  pathway-related molecules in tumor immunity, advances in drug research, combination therapies, and some new technology-related therapies.
AbstractList Nicotinamide adenine dinucleotide (NAD) is the core of cellular energy metabolism. NAMPT, Sirtuins, PARP, CD38, and other molecules in this classic metabolic pathway affect many key cellular functions and are closely related to the occurrence and development of many diseases. In recent years, several studies have found that these molecules can regulate cell energy metabolism, promote the release of related cytokines, induce the expression of neoantigens, change the tumor immune microenvironment (TIME), and then play an anticancer role. Drugs targeting these molecules are under development or approved for clinical use. Although there are some side effects and drug resistance, the discovery of novel drugs, the development of combination therapies, and the application of new technologies provide solutions to these challenges and improve efficacy. This review presents the mechanisms of action of NAD  pathway-related molecules in tumor immunity, advances in drug research, combination therapies, and some new technology-related therapies.
Nicotinamide adenine dinucleotide (NAD) is the core of cellular energy metabolism. NAMPT, Sirtuins, PARP, CD38, and other molecules in this classic metabolic pathway affect many key cellular functions and are closely related to the occurrence and development of many diseases. In recent years, several studies have found that these molecules can regulate cell energy metabolism, promote the release of related cytokines, induce the expression of neoantigens, change the tumor immune microenvironment (TIME), and then play an anticancer role. Drugs targeting these molecules are under development or approved for clinical use. Although there are some side effects and drug resistance, the discovery of novel drugs, the development of combination therapies, and the application of new technologies provide solutions to these challenges and improve efficacy. This review presents the mechanisms of action of NAD  pathway-related molecules in tumor immunity, advances in drug research, combination therapies, and some new technology-related therapies.Nicotinamide adenine dinucleotide (NAD) is the core of cellular energy metabolism. NAMPT, Sirtuins, PARP, CD38, and other molecules in this classic metabolic pathway affect many key cellular functions and are closely related to the occurrence and development of many diseases. In recent years, several studies have found that these molecules can regulate cell energy metabolism, promote the release of related cytokines, induce the expression of neoantigens, change the tumor immune microenvironment (TIME), and then play an anticancer role. Drugs targeting these molecules are under development or approved for clinical use. Although there are some side effects and drug resistance, the discovery of novel drugs, the development of combination therapies, and the application of new technologies provide solutions to these challenges and improve efficacy. This review presents the mechanisms of action of NAD  pathway-related molecules in tumor immunity, advances in drug research, combination therapies, and some new technology-related therapies.
Abstract Nicotinamide adenine dinucleotide (NAD) is the core of cellular energy metabolism. NAMPT, Sirtuins, PARP, CD38, and other molecules in this classic metabolic pathway affect many key cellular functions and are closely related to the occurrence and development of many diseases. In recent years, several studies have found that these molecules can regulate cell energy metabolism, promote the release of related cytokines, induce the expression of neoantigens, change the tumor immune microenvironment (TIME), and then play an anticancer role. Drugs targeting these molecules are under development or approved for clinical use. Although there are some side effects and drug resistance, the discovery of novel drugs, the development of combination therapies, and the application of new technologies provide solutions to these challenges and improve efficacy. This review presents the mechanisms of action of NAD  pathway-related molecules in tumor immunity, advances in drug research, combination therapies, and some new technology-related therapies.
ArticleNumber 242
Author Xu, QinChen
Ren, Yidan
Mohseni, Ghazal
Hao, Xiaodong
Liu, Xiaoyan
Wang, Yunshan
Xu, Yiwei
Gao, Huiru
Wang, Qin
Author_xml – sequence: 1
  givenname: QinChen
  surname: Xu
  fullname: Xu, QinChen
– sequence: 2
  givenname: Xiaoyan
  surname: Liu
  fullname: Liu, Xiaoyan
– sequence: 3
  givenname: Ghazal
  surname: Mohseni
  fullname: Mohseni, Ghazal
– sequence: 4
  givenname: Xiaodong
  surname: Hao
  fullname: Hao, Xiaodong
– sequence: 5
  givenname: Yidan
  surname: Ren
  fullname: Ren, Yidan
– sequence: 6
  givenname: Yiwei
  surname: Xu
  fullname: Xu, Yiwei
– sequence: 7
  givenname: Huiru
  surname: Gao
  fullname: Gao, Huiru
– sequence: 8
  givenname: Qin
  surname: Wang
  fullname: Wang, Qin
– sequence: 9
  givenname: Yunshan
  surname: Wang
  fullname: Wang, Yunshan
BookMark eNp9kstu1TAQhiNURC_wAqwssWET8CXxZYNUlVulAhtYWxNnco5LYh9sp6hvj09PhWgXyBrZmvnn03j0nzZHIQZsmpeMvmFMy7eZcSP6lnJeQ8quZU-aE9apvuVaqqN_3sfNac7XlDKlJX3WHIveUCk5P2l-fkG3heDzQhJmhOS2BMJISkIoC4ZCdiluaimTOJGv5-_JDsr2N9xW-QwFR7LEGd06YyY-kLIuMRG_LGtAsniXIoYbn2LYo543TyeYM764v8-aHx8_fL_43F59-3R5cX7Vul51pWVSOUZ7hSAniROaQQzMCCcHzZx2AApA60FpI-jI0CjlXI8OBjGKHoQWZ83lgTtGuLa75BdItzaCt3eJmDYWUvFuRovjoLt-7JCbsVOSDjgaTfvByEn0cqKV9e7A2q3DgqOr30gwP4A-rAS_tZt4Y40QWnayAl7fA1L8tWIudvHZ4TxDwLhmy6WRuq-HVemrR9LruKZQV2W5oh3VouO8qvhBVZebc8Lp7zCM2r0v7MEXtvrC3vnC7tH6UZPzBYqP-6H9_L_WP81IwBg
CitedBy_id crossref_primary_10_1016_j_clnu_2023_08_017
crossref_primary_10_3390_cancers16173085
crossref_primary_10_3389_fimmu_2024_1452303
crossref_primary_10_1186_s13048_025_01596_4
crossref_primary_10_1016_j_bbadis_2024_167106
crossref_primary_10_1002_jor_25757
crossref_primary_10_3389_fphys_2024_1415037
Cites_doi 10.1038/s41419-021-03968-2
10.1021/acs.jmedchem.0c01183
10.1007/s12012-016-9387-6
10.1002/ijc.31808
10.3892/or.2011.1378
10.1016/j.celrep.2021.109516
10.1038/srep41962
10.1038/s41467-017-00396-9
10.1002/hep.30622
10.3109/15376516.2015.1014080
10.1160/th13-07-0531
10.1016/j.canlet.2016.05.024
10.1016/j.cmet.2017.10.006
10.1146/annurev.nutr.28.061807.155443
10.3390/cells9010052
10.1016/j.ccell.2018.05.008
10.1016/j.molimm.2007.10.044
10.1016/j.cmet.2016.05.006
10.1038/s41419-021-03901-7
10.1053/j.gastro.2018.05.024
10.18632/oncotarget.20577
10.7150/ijbs.49735
10.1002/jcp.27782
10.1038/nrc3340
10.1021/acs.jmedchem.7b00467
10.1007/s00262-021-02852-4
10.1111/bjh.16044
10.1038/nature03443
10.1021/acs.jmedchem.6b01609
10.1038/45582
10.1038/s41586-019-1150-2
10.1016/j.exger.2006.06.003
10.1158/0008-5472.Can-18-1544
10.1016/j.celrep.2017.04.004
10.1158/0008-5472.Can-16-3079
10.1165/rcmb.2017-0155OC
10.18632/oncotarget.6538
10.7150/thno.53886
10.1021/acs.bioconjchem.2c00178
10.1016/j.micpath.2018.02.002
10.1182/bloodadvances.2018024182
10.1038/s41467-018-02915-8
10.3389/fimmu.2020.02168
10.1002/jcp.25016
10.1016/j.neuroscience.2017.05.022
10.4049/jimmunol.1801107
10.1016/j.apsb.2021.12.017
10.1021/acsmedchemlett.8b00254
10.1002/med.21753
10.1093/neuonc/noaa180
10.1016/j.cmet.2020.07.008
10.1158/1535-7163.Mct-09-1130
10.1158/0008-5472.Can-14-0839
10.1016/j.molcel.2015.06.012
10.1208/aapsj0902015
10.1021/acs.jmedchem.6b01392
10.3389/fcell.2021.813233
10.1073/pnas.0806092105
10.7150/thno.36281
10.1038/s41571-021-00532-x
10.1038/nri1983
10.1093/intimm/10.4.453
10.1002/jcp.27923
10.1016/j.bbrc.2006.05.100
10.1073/pnas.1805751115
10.1016/j.cmet.2015.04.002
10.1126/scisignal.2002700
10.1158/2159-8290.Cd-18-1218
10.3389/fphar.2019.00097
10.1038/leu.2011.205
10.1016/s0952-7915(99)80046-6
10.1016/j.ejmech.2020.113022
10.1038/s41580-020-00313-x
10.1074/jbc.M408388200
10.1038/bjc.2017.356
10.18632/oncotarget.9750
10.1016/j.ijbiomac.2019.08.061
10.1186/s12967-015-0583-0
10.1007/s10637-007-9083-2
10.1016/j.celrep.2018.11.054
10.1126/science.271.5256.1734
10.1038/srep13135
10.1161/circulationaha.116.024557
10.1158/2159-8290.Cd-17-0146
10.1038/s41467-018-03917-2
10.1111/imr.12389
10.1016/j.bbagen.2014.11.007
10.1164/rccm.200404-563OC
10.1096/fj.201800321R
10.7150/thno.44043
10.1152/physrev.00035.2007
10.1126/science.275.5297.218
10.1210/me.2007-0079
10.1001/jamaoncol.2019.1048
10.1016/s0145-2126(00)00093-x
10.1158/1535-7163.Mct-16-0674
10.1056/NEJMoa1706450
10.1158/1078-0432.Ccr-17-0544
10.1158/1078-0432.Ccr-16-3215
10.1016/j.ccell.2018.03.012
10.1084/jem.192.7.1027
10.1111/imr.12520
10.1182/blood-2014-07-589069
10.1155/2012/321653
10.1016/j.canlet.2021.04.007
10.1016/j.ejmech.2019.07.024
10.1155/2016/3031459
10.1016/j.biomaterials.2020.120140
10.4049/jimmunol.178.3.1748
10.1093/toxsci/kfx212
10.1016/j.ccr.2011.02.014
10.2174/138161210791208947
10.1158/1078-0432.Ccr-18-3412
10.1016/S0021-9258(18)64790-8
10.1016/j.smim.2017.12.004
10.1002/j.1460-2075.1992.tb05530.x
10.1038/s41401-020-0442-2
10.1016/s0065-2571(00)00013-3
10.1038/s41556-019-0299-0
10.15252/embj.2019103479
10.1097/CJI.0b013e3181adaff1
10.1007/s00262-021-02949-w
10.2217/imt.15.32
10.1016/j.ymthe.2020.01.018
10.1016/j.cell.2011.02.013
10.1111/jpi.12755
10.3390/ijms20030518
10.1007/s00280-009-1125-3
10.1111/pcmr.12037
10.1038/s41375-019-0692-5
10.1038/35051100
10.1165/rcmb.2014-0117OC
10.2174/092986711795590138
10.1016/j.cmet.2020.10.021
10.1164/rccm.200712-1822OC
10.1128/mcb.14.2.1431-1437.1994
10.1158/0008-5472.Can-20-1094
10.1634/theoncologist.2017-0328
10.1038/s41375-020-0810-4
10.1016/j.toxlet.2016.12.010
10.1158/1078-0432.Ccr-17-1121
10.1016/j.pharmthera.2015.02.004
10.1158/2159-8290.Cd-17-1033
10.1158/2159-8290.Cd-nb2016-164
10.1634/theoncologist.2017-0229
10.1158/0008-5472.Can-19-3188
10.1158/1078-0432.Ccr-18-2752
10.1038/ni987
10.1073/pnas.192461099
10.1038/cddis.2013.131
10.1016/j.celrep.2016.11.010
10.1016/j.ijrobp.2020.01.030
10.1007/s00262-021-02862-2
10.18632/oncotarget.7277
10.1021/acs.jmedchem.1c00017
10.1016/j.ejmech.2018.06.041
10.3892/or.2015.4053
10.1124/mol.110.065961
10.1126/science.124.3215.269
10.1007/s00204-016-1784-x
10.1111/imm.12099
10.1111/j.1600-0463.2011.02733.x
10.1158/0008-5472.Can-18-2558
10.1038/nrendo.2015.117
10.1016/j.bbrc.2006.08.066
10.1158/1535-7163.Mct-18-0643
10.1038/s41423-019-0224-2
10.1158/0008-5472.Can-18-1003
10.3389/fimmu.2019.01187
10.1056/NEJMoa1607751
10.1158/1078-0432.Ccr-14-0695
10.1158/1078-0432.Ccr-16-3192
10.1016/j.bcp.2020.114359
10.1038/leu.2015.240
10.1038/nature03445
10.18632/oncotarget.4693
10.2967/jnumed.116.177584
10.1016/j.freeradbiomed.2017.04.018
10.1038/s41388-020-1175-x
10.1074/jbc.M114.594721
10.1158/1940-6207.Capr-08-0160
10.1016/s1470-2045(14)70391-2
ContentType Journal Article
Copyright 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022. The Author(s).
The Author(s) 2022
Copyright_xml – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022. The Author(s).
– notice: The Author(s) 2022
DBID AAYXX
CITATION
3V.
7TM
7TO
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12935-022-02664-1
DatabaseName CrossRef
ProQuest Central (Corporate)
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
MEDLINE - Academic

CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1475-2867
EndPage 21
ExternalDocumentID oai_doaj_org_article_edb845d4e29d4760bed9805b96f356f0
PMC9338646
10_1186_s12935_022_02664_1
GrantInformation_xml – fundername: ;
  grantid: ZR2020MH007
– fundername: ;
  grantid: 81874040, 82172350; 81874040, 82172350
– fundername: ;
  grantid: 2019GSF108218, 2019GSF108139
GroupedDBID ---
0R~
29B
2WC
53G
5GY
5VS
6J9
7X7
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
ISR
ITC
KQ8
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
~8M
3V.
7TM
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c574t-167c1057ea6f6efe9b3b193c6b81c8caa7aa88b78930d1e977cc5ecab3d35a383
IEDL.DBID M48
ISSN 1475-2867
IngestDate Wed Aug 27 01:21:09 EDT 2025
Thu Aug 21 14:33:06 EDT 2025
Fri Jul 11 06:53:10 EDT 2025
Sun Jun 29 16:13:03 EDT 2025
Tue Jul 01 02:41:54 EDT 2025
Thu Apr 24 22:53:30 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c574t-167c1057ea6f6efe9b3b193c6b81c8caa7aa88b78930d1e977cc5ecab3d35a383
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12935-022-02664-1
PMID 35906622
PQID 2704083422
PQPubID 42567
PageCount 21
ParticipantIDs doaj_primary_oai_doaj_org_article_edb845d4e29d4760bed9805b96f356f0
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9338646
proquest_miscellaneous_2696858581
proquest_journals_2704083422
crossref_primary_10_1186_s12935_022_02664_1
crossref_citationtrail_10_1186_s12935_022_02664_1
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-07-30
PublicationDateYYYYMMDD 2022-07-30
PublicationDate_xml – month: 07
  year: 2022
  text: 2022-07-30
  day: 30
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Cancer cell international
PublicationYear 2022
Publisher BioMed Central
BMC
Publisher_xml – name: BioMed Central
– name: BMC
References J Lee (2664_CR113) 2018; 155
J Zhou (2664_CR11) 2018; 35
K Mihara (2664_CR164) 2012; 26
A Sánchez-Fueyo (2664_CR18) 2003; 4
S Sinha (2664_CR128) 2019; 140
L Bai (2664_CR73) 2016; 7
C Travelli (2664_CR50) 2019; 79
O Fortunato (2664_CR96) 2020; 11
K Tzogani (2664_CR157) 2018; 23
HN Jayaram (2664_CR5) 2011; 18
SR Mitchell (2664_CR108) 2019; 3
M Robson (2664_CR134) 2017; 377
DL Misner (2664_CR103) 2017; 17
CS Neumann (2664_CR181) 2018; 17
H Farmer (2664_CR144) 2005; 434
M Li (2664_CR174) 2020; 80
E Limagne (2664_CR68) 2017; 19
D Hollenbaugh (2664_CR24) 1992; 11
S Rottenberg (2664_CR137) 2008; 105
Y Iwai (2664_CR25) 2002; 99
FA Kunze (2664_CR83) 2019; 202
G Liu (2664_CR65) 2021; 41
S Jiao (2664_CR149) 2017; 23
TH Watts (2664_CR15) 1999; 11
M Jang (2664_CR115) 1997; 275
P Wu (2664_CR170) 2021; 70
D Soncini (2664_CR41) 2014; 289
MA Dimopoulos (2664_CR158) 2016; 375
JR Revollo (2664_CR4) 2004; 279
SM Camp (2664_CR43) 2015; 5
R Valdor (2664_CR82) 2008; 45
SB Hong (2664_CR45) 2008; 178
JF Liu (2664_CR153) 2014; 15
A Lucena-Cacace (2664_CR38) 2017; 8
I Alvarado-Cruz (2664_CR148) 2021; 184
B Heyman (2664_CR84) 2019; 38
JA Kaleeba (2664_CR22) 1998; 10
HE Bryant (2664_CR143) 2005; 434
E Safari (2664_CR12) 2019; 234
S Aras (2664_CR28) 2017; 117
C Dong (2664_CR20) 2001; 409
D Viola (2664_CR155) 2021; 35
P Aksoy (2664_CR88) 2006; 349
S Cassar (2664_CR104) 2018; 161
J Shen (2664_CR147) 2019; 79
CM Heske (2664_CR165) 2017; 23
L Ding (2664_CR146) 2018; 25
B Samal (2664_CR33) 1994; 14
O Warburg (2664_CR6) 1956; 124
AR Moschen (2664_CR54) 2010; 16
Z Wu (2664_CR150) 2021; 70
AR Moschen (2664_CR55) 2007; 178
MP Dias (2664_CR142) 2021; 18
VP Torchilin (2664_CR176) 2007; 9
A Chiarugi (2664_CR29) 2012; 12
DS Thommen (2664_CR169) 2018; 33
SQ Ye (2664_CR46) 2005; 171
CL Zuch de Zafra (2664_CR162) 2019; 25
X Feng (2664_CR93) 2017; 23
L Ma (2664_CR117) 2019; 10
XT Wu (2664_CR35) 2018; 117
D Quigley (2664_CR141) 2017; 7
H Maeda (2664_CR177) 2001; 41
V Bhatnagar (2664_CR156) 2017; 22
N Böhnke (2664_CR183) 2022; 33
F Ye (2664_CR66) 2020; 28
NW van de Donk (2664_CR154) 2016; 270
X Tang (2664_CR74) 2017; 8
A von Heideman (2664_CR100) 2010; 65
LW Finley (2664_CR70) 2011; 19
C Pantelidou (2664_CR151) 2019; 9
M Schacke (2664_CR80) 2019
X Chen (2664_CR120) 2021; 71
K van de Ven (2664_CR23) 2015; 7
HK Park (2664_CR63) 2019; 79
JJ Miller (2664_CR59) 2021; 23
KL Bogan (2664_CR2) 2008; 28
E Pylaeva (2664_CR53) 2019; 144
A Bishayee (2664_CR114) 2009; 2
RC Oita (2664_CR48) 2018; 59
CM Daniels (2664_CR75) 2015; 58
TH Kim (2664_CR124) 2015; 1850
H Wang (2664_CR179) 2018; 9
AS Karpov (2664_CR182) 2018; 9
L Korotchkina (2664_CR105) 2020; 34
G Habif (2664_CR26) 2019; 16
J Navarro (2664_CR81) 2017; 7
AK Elf (2664_CR171) 2017; 58
D Hanahan (2664_CR7) 2011; 144
D Zhang (2664_CR178) 2019; 9
M Das (2664_CR19) 2017; 276
F Malavasi (2664_CR91) 2008; 88
YJ Zhao (2664_CR89) 2012; 5
F Piacente (2664_CR112) 2017; 77
AJ Covarrubias (2664_CR1) 2021; 22
J Camacho-Pereira (2664_CR86) 2016; 23
N Zhang (2664_CR118) 2017; 267
TQ Bi (2664_CR37) 2011; 26
G Cheng (2664_CR42) 2015; 34
MJ Yoon (2664_CR51) 2015; 21
K Mihara (2664_CR163) 2009; 32
R Palmirotta (2664_CR122) 2016; 2016
G Zhao (2664_CR106) 2017; 16
S Chowdhry (2664_CR9) 2019; 569
I Hamaidi (2664_CR62) 2020; 32
D Sampath (2664_CR98) 2015; 151
I Voskoboinik (2664_CR27) 2006; 6
S Sun (2664_CR121) 2022; 12
A Nencioni (2664_CR31) 2014; 111
TW Wang (2664_CR61) 2020; 80
L Chen (2664_CR166) 2018; 8
Y Song (2664_CR180) 2020; 254
UH Olesen (2664_CR40) 2011; 119
A Garten (2664_CR8) 2015; 11
E Maldi (2664_CR39) 2013; 26
F Meng (2664_CR67) 2021; 70
UH Olesen (2664_CR101) 2010; 9
Y Wu (2664_CR107) 2022; 12
A Mangerich (2664_CR78) 2012; 2012
H Yang (2664_CR30) 2006; 41
HQ Ju (2664_CR36) 2016; 379
Q Han (2664_CR175) 2021; 11
C Jiang (2664_CR69) 2020; 16
J Preiss (2664_CR3) 1958; 233
KA Hogan (2664_CR90) 2019; 10
K Holen (2664_CR99) 2008; 26
GM Shankar (2664_CR173) 2018; 115
JM Tarrant (2664_CR102) 2015; 25
LL Yang (2664_CR131) 2018; 155
SJ Pettitt (2664_CR138) 2018; 9
V Audrito (2664_CR49) 2015; 125
Y Tong (2664_CR72) 2021; 12
L Liu (2664_CR71) 2021; 510
B Farhood (2664_CR14) 2019; 234
X Sun (2664_CR47) 2014; 51
L Gao (2664_CR97) 2021; 12
M Spinck (2664_CR129) 2021; 64
L Wei (2664_CR119) 2013; 4
H Lv (2664_CR56) 2021; 33
X Liu (2664_CR95) 2016; 17
S Duarte-Pereira (2664_CR111) 2016; 7
F Morandi (2664_CR168) 2015; 6
J Chen (2664_CR44) 2017; 135
JE Jaspers (2664_CR136) 2015; 75
Y Wang (2664_CR57) 2021; 36
L Moreno-Lama (2664_CR85) 2020; 39
B Weigelt (2664_CR140) 2017; 23
MM Rosado (2664_CR77) 2013; 139
PA Konstantinopoulos (2664_CR152) 2019; 5
MA Ghonim (2664_CR76) 2015; 13
JM Konen (2664_CR94) 2019
J Shang (2664_CR126) 2020; 10
H Jiang (2664_CR161) 2016; 30
WK Oh (2664_CR123) 2010; 78
A Manna (2664_CR159) 2019; 25
J Ma (2664_CR64) 2019; 187
GS Young (2664_CR87) 2006; 346
CM Deus (2664_CR116) 2017; 91
X Chen (2664_CR133) 2020; 63
D Wolf (2664_CR10) 2015; 230
S Chatterjee (2664_CR167) 2018; 27
C Zhang (2664_CR125) 2021; 9
SN Seyedin (2664_CR172) 2020; 108
CX Chen (2664_CR34) 2017; 356
S Deaglio (2664_CR92) 2001; 25
G Sociali (2664_CR52) 2019; 33
KC Strickland (2664_CR145) 2016; 7
C Travelli (2664_CR32) 2017; 60
E Hocsak (2664_CR79) 2017; 108
M Delman (2664_CR132) 2019; 180
Z Wei (2664_CR60) 2019; 70
SK Yoshinaga (2664_CR21) 1999; 402
H Yamamoto (2664_CR58) 2007; 21
DR Leach (2664_CR16) 1996; 271
W Zhang (2664_CR110) 2021; 211
J Deckert (2664_CR160) 2014; 20
GJ Freeman (2664_CR17) 2000; 192
E Gogola (2664_CR139) 2018; 33
2664_CR135
G Dong (2664_CR109) 2017; 60
JL Shang (2664_CR127) 2021; 42
S Moniot (2664_CR130) 2017; 60
F Chen (2664_CR13) 2019; 21
References_xml – volume: 12
  start-page: 680
  issue: 7
  year: 2021
  ident: 2664_CR97
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-021-03968-2
– volume: 63
  start-page: 10474
  issue: 18
  year: 2020
  ident: 2664_CR133
  publication-title: J Med Chem
  doi: 10.1021/acs.jmedchem.0c01183
– volume: 17
  start-page: 307
  issue: 3
  year: 2017
  ident: 2664_CR103
  publication-title: Cardiovasc Toxicol
  doi: 10.1007/s12012-016-9387-6
– volume: 144
  start-page: 136
  issue: 1
  year: 2019
  ident: 2664_CR53
  publication-title: Int J Cancer
  doi: 10.1002/ijc.31808
– volume: 26
  start-page: 1251
  issue: 5
  year: 2011
  ident: 2664_CR37
  publication-title: Oncol Rep
  doi: 10.3892/or.2011.1378
– volume: 36
  start-page: 109516.DOI
  issue: 6
  year: 2021
  ident: 2664_CR57
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2021.109516
– volume: 7
  start-page: 41962.DOI
  year: 2017
  ident: 2664_CR81
  publication-title: Sci Rep
  doi: 10.1038/srep41962
– volume: 8
  start-page: 318
  issue: 1
  year: 2017
  ident: 2664_CR74
  publication-title: Nat Commun
  doi: 10.1038/s41467-017-00396-9
– volume: 70
  start-page: 1197
  issue: 4
  year: 2019
  ident: 2664_CR60
  publication-title: Hepatology
  doi: 10.1002/hep.30622
– volume: 25
  start-page: 201
  issue: 3
  year: 2015
  ident: 2664_CR102
  publication-title: Toxicol Mech Methods
  doi: 10.3109/15376516.2015.1014080
– volume: 111
  start-page: 308
  issue: 2
  year: 2014
  ident: 2664_CR31
  publication-title: Thromb Haemost
  doi: 10.1160/th13-07-0531
– volume: 379
  start-page: 1
  issue: 1
  year: 2016
  ident: 2664_CR36
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2016.05.024
– volume: 27
  start-page: 85
  issue: 1
  year: 2018
  ident: 2664_CR167
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2017.10.006
– volume: 28
  start-page: 115
  year: 2008
  ident: 2664_CR2
  publication-title: Annu Rev Nutr
  doi: 10.1146/annurev.nutr.28.061807.155443
– year: 2019
  ident: 2664_CR94
  publication-title: Cells.
  doi: 10.3390/cells9010052
– volume: 33
  start-page: 1078
  issue: 6
  year: 2018
  ident: 2664_CR139
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2018.05.008
– volume: 45
  start-page: 1863
  issue: 7
  year: 2008
  ident: 2664_CR82
  publication-title: Mol Immunol
  doi: 10.1016/j.molimm.2007.10.044
– volume: 12
  start-page: 2310
  issue: 5
  year: 2022
  ident: 2664_CR121
  publication-title: Am J Cancer Res
– volume: 23
  start-page: 1127
  issue: 6
  year: 2016
  ident: 2664_CR86
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2016.05.006
– volume: 12
  start-page: 621
  issue: 7
  year: 2021
  ident: 2664_CR72
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-021-03901-7
– volume: 155
  start-page: 799
  issue: 3
  year: 2018
  ident: 2664_CR113
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2018.05.024
– volume: 8
  start-page: 99514
  issue: 59
  year: 2017
  ident: 2664_CR38
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.20577
– volume: 16
  start-page: 3075
  issue: 15
  year: 2020
  ident: 2664_CR69
  publication-title: Int J Biol Sci
  doi: 10.7150/ijbs.49735
– volume: 234
  start-page: 8509
  issue: 6
  year: 2019
  ident: 2664_CR14
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.27782
– volume: 12
  start-page: 741
  issue: 11
  year: 2012
  ident: 2664_CR29
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3340
– volume: 60
  start-page: 7965
  issue: 19
  year: 2017
  ident: 2664_CR109
  publication-title: J Med Chem
  doi: 10.1021/acs.jmedchem.7b00467
– volume: 70
  start-page: 2971
  issue: 10
  year: 2021
  ident: 2664_CR150
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-021-02852-4
– volume: 187
  start-page: 49
  issue: 1
  year: 2019
  ident: 2664_CR64
  publication-title: Br J Haematol
  doi: 10.1111/bjh.16044
– volume: 434
  start-page: 913
  issue: 7035
  year: 2005
  ident: 2664_CR143
  publication-title: Nature
  doi: 10.1038/nature03443
– volume: 60
  start-page: 2344
  issue: 6
  year: 2017
  ident: 2664_CR130
  publication-title: J Med Chem
  doi: 10.1021/acs.jmedchem.6b01609
– volume: 402
  start-page: 827
  issue: 6763
  year: 1999
  ident: 2664_CR21
  publication-title: Nature
  doi: 10.1038/45582
– volume: 569
  start-page: 570
  issue: 7757
  year: 2019
  ident: 2664_CR9
  publication-title: Nature
  doi: 10.1038/s41586-019-1150-2
– volume: 41
  start-page: 718
  issue: 8
  year: 2006
  ident: 2664_CR30
  publication-title: Exp Gerontol
  doi: 10.1016/j.exger.2006.06.003
– volume: 79
  start-page: 1938
  issue: 8
  year: 2019
  ident: 2664_CR50
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.Can-18-1544
– volume: 19
  start-page: 746
  issue: 4
  year: 2017
  ident: 2664_CR68
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2017.04.004
– volume: 77
  start-page: 3857
  issue: 14
  year: 2017
  ident: 2664_CR112
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.Can-16-3079
– volume: 59
  start-page: 36
  issue: 1
  year: 2018
  ident: 2664_CR48
  publication-title: Am J Respir Cell Mol Biol
  doi: 10.1165/rcmb.2017-0155OC
– volume: 7
  start-page: 1973
  issue: 2
  year: 2016
  ident: 2664_CR111
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.6538
– volume: 11
  start-page: 6526
  issue: 13
  year: 2021
  ident: 2664_CR175
  publication-title: Theranostics
  doi: 10.7150/thno.53886
– volume: 33
  start-page: 1210
  issue: 6
  year: 2022
  ident: 2664_CR183
  publication-title: Bioconjug Chem
  doi: 10.1021/acs.bioconjchem.2c00178
– volume: 117
  start-page: 55
  year: 2018
  ident: 2664_CR35
  publication-title: Microb Pathog
  doi: 10.1016/j.micpath.2018.02.002
– volume: 3
  start-page: 242
  issue: 3
  year: 2019
  ident: 2664_CR108
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2018024182
– volume: 9
  start-page: 562
  issue: 1
  year: 2018
  ident: 2664_CR179
  publication-title: Nat Commun
  doi: 10.1038/s41467-018-02915-8
– volume: 11
  start-page: 02168.
  year: 2020
  ident: 2664_CR96
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2020.02168
– volume: 230
  start-page: 2598
  issue: 11
  year: 2015
  ident: 2664_CR10
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.25016
– volume: 356
  start-page: 193
  year: 2017
  ident: 2664_CR34
  publication-title: Neuroscience
  doi: 10.1016/j.neuroscience.2017.05.022
– volume: 202
  start-page: 1406
  issue: 5
  year: 2019
  ident: 2664_CR83
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1801107
– volume: 12
  start-page: 2859
  issue: 6
  year: 2022
  ident: 2664_CR107
  publication-title: Acta Pharm Sin B
  doi: 10.1016/j.apsb.2021.12.017
– volume: 9
  start-page: 838
  issue: 8
  year: 2018
  ident: 2664_CR182
  publication-title: ACS Med Chem Lett
  doi: 10.1021/acsmedchemlett.8b00254
– volume: 41
  start-page: 1089
  issue: 2
  year: 2021
  ident: 2664_CR65
  publication-title: Med Res Rev
  doi: 10.1002/med.21753
– volume: 23
  start-page: 53
  issue: 1
  year: 2021
  ident: 2664_CR59
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/noaa180
– volume: 32
  start-page: 420
  issue: 3
  year: 2020
  ident: 2664_CR62
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2020.07.008
– volume: 9
  start-page: 1609
  issue: 6
  year: 2010
  ident: 2664_CR101
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.Mct-09-1130
– volume: 75
  start-page: 732
  issue: 4
  year: 2015
  ident: 2664_CR136
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.Can-14-0839
– volume: 58
  start-page: 911
  issue: 6
  year: 2015
  ident: 2664_CR75
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2015.06.012
– volume: 9
  start-page: E128-47
  issue: 2
  year: 2007
  ident: 2664_CR176
  publication-title: Aaps j
  doi: 10.1208/aapsj0902015
– volume: 60
  start-page: 1768
  issue: 5
  year: 2017
  ident: 2664_CR32
  publication-title: J Med Chem
  doi: 10.1021/acs.jmedchem.6b01392
– volume: 9
  start-page: 813233.DOI
  year: 2021
  ident: 2664_CR125
  publication-title: Front Cell Dev Biol
  doi: 10.3389/fcell.2021.813233
– volume: 105
  start-page: 17079
  issue: 44
  year: 2008
  ident: 2664_CR137
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0806092105
– volume: 9
  start-page: 6224
  issue: 21
  year: 2019
  ident: 2664_CR178
  publication-title: Theranostics
  doi: 10.7150/thno.36281
– volume: 18
  start-page: 773
  issue: 12
  year: 2021
  ident: 2664_CR142
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-021-00532-x
– volume: 6
  start-page: 940
  issue: 12
  year: 2006
  ident: 2664_CR27
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri1983
– volume: 10
  start-page: 453
  issue: 4
  year: 1998
  ident: 2664_CR22
  publication-title: Int Immunol
  doi: 10.1093/intimm/10.4.453
– volume: 234
  start-page: 9966
  issue: 7
  year: 2019
  ident: 2664_CR12
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.27923
– volume: 346
  start-page: 188
  issue: 1
  year: 2006
  ident: 2664_CR87
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2006.05.100
– volume: 115
  start-page: E8388-e94
  issue: 36
  year: 2018
  ident: 2664_CR173
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1805751115
– volume: 21
  start-page: 706
  issue: 5
  year: 2015
  ident: 2664_CR51
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2015.04.002
– volume: 5
  start-page: ra67
  issue: 241
  year: 2012
  ident: 2664_CR89
  publication-title: Sci Signal
  doi: 10.1126/scisignal.2002700
– volume: 9
  start-page: 722
  issue: 6
  year: 2019
  ident: 2664_CR151
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.Cd-18-1218
– volume: 10
  start-page: 97.DOI
  year: 2019
  ident: 2664_CR117
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2019.00097
– volume: 26
  start-page: 365
  issue: 2
  year: 2012
  ident: 2664_CR164
  publication-title: Leukemia
  doi: 10.1038/leu.2011.205
– volume: 11
  start-page: 286
  issue: 3
  year: 1999
  ident: 2664_CR15
  publication-title: Curr Opin Immunol
  doi: 10.1016/s0952-7915(99)80046-6
– volume: 211
  start-page: 113022.DOI
  year: 2021
  ident: 2664_CR110
  publication-title: Eur J Med Chem
  doi: 10.1016/j.ejmech.2020.113022
– volume: 22
  start-page: 119
  issue: 2
  year: 2021
  ident: 2664_CR1
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/s41580-020-00313-x
– volume: 279
  start-page: 50754
  issue: 49
  year: 2004
  ident: 2664_CR4
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M408388200
– volume: 117
  start-page: 1583
  issue: 11
  year: 2017
  ident: 2664_CR28
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2017.356
– volume: 7
  start-page: 40377
  issue: 26
  year: 2016
  ident: 2664_CR73
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.9750
– volume: 140
  start-page: 454
  year: 2019
  ident: 2664_CR128
  publication-title: Int J Biol Macromol
  doi: 10.1016/j.ijbiomac.2019.08.061
– volume: 13
  start-page: 225.
  year: 2015
  ident: 2664_CR76
  publication-title: J Transl Med
  doi: 10.1186/s12967-015-0583-0
– volume: 26
  start-page: 45
  issue: 1
  year: 2008
  ident: 2664_CR99
  publication-title: Invest New Drugs
  doi: 10.1007/s10637-007-9083-2
– volume: 25
  start-page: 2972
  issue: 11
  year: 2018
  ident: 2664_CR146
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2018.11.054
– volume: 271
  start-page: 1734
  issue: 5256
  year: 1996
  ident: 2664_CR16
  publication-title: Science
  doi: 10.1126/science.271.5256.1734
– volume: 5
  start-page: 13135.DOI
  year: 2015
  ident: 2664_CR43
  publication-title: Sci Rep
  doi: 10.1038/srep13135
– volume: 135
  start-page: 1532
  issue: 16
  year: 2017
  ident: 2664_CR44
  publication-title: Circulation
  doi: 10.1161/circulationaha.116.024557
– volume: 7
  start-page: 999
  issue: 9
  year: 2017
  ident: 2664_CR141
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.Cd-17-0146
– volume: 9
  start-page: 1849
  issue: 1
  year: 2018
  ident: 2664_CR138
  publication-title: Nat Commun
  doi: 10.1038/s41467-018-03917-2
– volume: 270
  start-page: 95
  issue: 1
  year: 2016
  ident: 2664_CR154
  publication-title: Immunol Rev
  doi: 10.1111/imr.12389
– volume: 1850
  start-page: 401
  issue: 2
  year: 2015
  ident: 2664_CR124
  publication-title: Biochim Biophys Acta
  doi: 10.1016/j.bbagen.2014.11.007
– volume: 171
  start-page: 361
  issue: 4
  year: 2005
  ident: 2664_CR46
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.200404-563OC
– volume: 33
  start-page: 3704
  issue: 3
  year: 2019
  ident: 2664_CR52
  publication-title: FASEB J
  doi: 10.1096/fj.201800321R
– volume: 10
  start-page: 5845
  issue: 13
  year: 2020
  ident: 2664_CR126
  publication-title: Theranostics
  doi: 10.7150/thno.44043
– volume: 88
  start-page: 841
  issue: 3
  year: 2008
  ident: 2664_CR91
  publication-title: Physiol Rev
  doi: 10.1152/physrev.00035.2007
– volume: 275
  start-page: 218
  issue: 5297
  year: 1997
  ident: 2664_CR115
  publication-title: Science
  doi: 10.1126/science.275.5297.218
– volume: 21
  start-page: 1745
  issue: 8
  year: 2007
  ident: 2664_CR58
  publication-title: Mol Endocrinol.
  doi: 10.1210/me.2007-0079
– volume: 5
  start-page: 1141
  issue: 8
  year: 2019
  ident: 2664_CR152
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2019.1048
– volume: 25
  start-page: 1
  issue: 1
  year: 2001
  ident: 2664_CR92
  publication-title: Leuk Res
  doi: 10.1016/s0145-2126(00)00093-x
– volume: 16
  start-page: 2677
  issue: 12
  year: 2017
  ident: 2664_CR106
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.Mct-16-0674
– volume: 377
  start-page: 523
  issue: 6
  year: 2017
  ident: 2664_CR134
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1706450
– volume: 23
  start-page: 6708
  issue: 21
  year: 2017
  ident: 2664_CR140
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.Ccr-17-0544
– volume: 23
  start-page: 3711
  issue: 14
  year: 2017
  ident: 2664_CR149
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.Ccr-16-3215
– volume: 33
  start-page: 547
  issue: 4
  year: 2018
  ident: 2664_CR169
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2018.03.012
– volume: 192
  start-page: 1027
  issue: 7
  year: 2000
  ident: 2664_CR17
  publication-title: J Exp Med
  doi: 10.1084/jem.192.7.1027
– volume: 276
  start-page: 97
  issue: 1
  year: 2017
  ident: 2664_CR19
  publication-title: Immunol Rev
  doi: 10.1111/imr.12520
– volume: 125
  start-page: 111
  issue: 1
  year: 2015
  ident: 2664_CR49
  publication-title: Blood
  doi: 10.1182/blood-2014-07-589069
– volume: 2012
  start-page: 321653.DOI
  year: 2012
  ident: 2664_CR78
  publication-title: Oxid Med Cell Longev
  doi: 10.1155/2012/321653
– volume: 510
  start-page: 93
  year: 2021
  ident: 2664_CR71
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2021.04.007
– volume: 180
  start-page: 224
  year: 2019
  ident: 2664_CR132
  publication-title: Eur J Med Chem
  doi: 10.1016/j.ejmech.2019.07.024
– volume: 2016
  start-page: 3031459.DOI
  year: 2016
  ident: 2664_CR122
  publication-title: Oxid Med Cell Longev
  doi: 10.1155/2016/3031459
– volume: 254
  start-page: 120140.DOI
  year: 2020
  ident: 2664_CR180
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2020.120140
– volume: 178
  start-page: 1748
  issue: 3
  year: 2007
  ident: 2664_CR55
  publication-title: J Immunol
  doi: 10.4049/jimmunol.178.3.1748
– volume: 161
  start-page: 300
  issue: 2
  year: 2018
  ident: 2664_CR104
  publication-title: Toxicol Sci
  doi: 10.1093/toxsci/kfx212
– volume: 19
  start-page: 416
  issue: 3
  year: 2011
  ident: 2664_CR70
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2011.02.014
– volume: 16
  start-page: 1913
  issue: 17
  year: 2010
  ident: 2664_CR54
  publication-title: Curr Pharm Des
  doi: 10.2174/138161210791208947
– volume: 25
  start-page: 3974
  issue: 13
  year: 2019
  ident: 2664_CR159
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.Ccr-18-3412
– volume: 233
  start-page: 493
  issue: 2
  year: 1958
  ident: 2664_CR3
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(18)64790-8
– volume: 35
  start-page: 19
  year: 2018
  ident: 2664_CR11
  publication-title: Semin Immunol
  doi: 10.1016/j.smim.2017.12.004
– volume: 11
  start-page: 4313
  issue: 12
  year: 1992
  ident: 2664_CR24
  publication-title: Embo J
  doi: 10.1002/j.1460-2075.1992.tb05530.x
– volume: 42
  start-page: 120
  issue: 1
  year: 2021
  ident: 2664_CR127
  publication-title: Acta Pharmacol Sin
  doi: 10.1038/s41401-020-0442-2
– volume: 41
  start-page: 189
  year: 2001
  ident: 2664_CR177
  publication-title: Adv Enzyme Regul
  doi: 10.1016/s0065-2571(00)00013-3
– volume: 21
  start-page: 498
  issue: 4
  year: 2019
  ident: 2664_CR13
  publication-title: Nat Cell Biol
  doi: 10.1038/s41556-019-0299-0
– volume: 38
  start-page: e103479
  issue: 21
  year: 2019
  ident: 2664_CR84
  publication-title: Embo J
  doi: 10.15252/embj.2019103479
– volume: 32
  start-page: 737
  issue: 7
  year: 2009
  ident: 2664_CR163
  publication-title: J Immunother
  doi: 10.1097/CJI.0b013e3181adaff1
– volume: 70
  start-page: 3603
  issue: 12
  year: 2021
  ident: 2664_CR170
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-021-02949-w
– volume: 7
  start-page: 655
  issue: 6
  year: 2015
  ident: 2664_CR23
  publication-title: Immunotherapy
  doi: 10.2217/imt.15.32
– volume: 28
  start-page: 874
  issue: 3
  year: 2020
  ident: 2664_CR66
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2020.01.018
– volume: 144
  start-page: 646
  issue: 5
  year: 2011
  ident: 2664_CR7
  publication-title: Cell
  doi: 10.1016/j.cell.2011.02.013
– volume: 71
  start-page: e12755
  issue: 2
  year: 2021
  ident: 2664_CR120
  publication-title: J Pineal Res
  doi: 10.1111/jpi.12755
– year: 2019
  ident: 2664_CR80
  publication-title: Int J Mol Sci.
  doi: 10.3390/ijms20030518
– volume: 65
  start-page: 1165
  issue: 6
  year: 2010
  ident: 2664_CR100
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-009-1125-3
– volume: 26
  start-page: 144
  issue: 1
  year: 2013
  ident: 2664_CR39
  publication-title: Pigment Cell Melanoma Res
  doi: 10.1111/pcmr.12037
– volume: 34
  start-page: 1828
  issue: 7
  year: 2020
  ident: 2664_CR105
  publication-title: Leukemia
  doi: 10.1038/s41375-019-0692-5
– volume: 409
  start-page: 97
  issue: 6816
  year: 2001
  ident: 2664_CR20
  publication-title: Nature
  doi: 10.1038/35051100
– volume: 51
  start-page: 660
  issue: 5
  year: 2014
  ident: 2664_CR47
  publication-title: Am J Respir Cell Mol Biol
  doi: 10.1165/rcmb.2014-0117OC
– volume: 18
  start-page: 1962
  issue: 13
  year: 2011
  ident: 2664_CR5
  publication-title: Curr Med Chem
  doi: 10.2174/092986711795590138
– volume: 33
  start-page: 110
  issue: 1
  year: 2021
  ident: 2664_CR56
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2020.10.021
– volume: 178
  start-page: 605
  issue: 6
  year: 2008
  ident: 2664_CR45
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.200712-1822OC
– volume: 14
  start-page: 1431
  issue: 2
  year: 1994
  ident: 2664_CR33
  publication-title: Mol Cell Biol
  doi: 10.1128/mcb.14.2.1431-1437.1994
– volume: 80
  start-page: 5024
  issue: 22
  year: 2020
  ident: 2664_CR174
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.Can-20-1094
– volume: 23
  start-page: 594
  issue: 5
  year: 2018
  ident: 2664_CR157
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2017-0328
– volume: 35
  start-page: 189
  issue: 1
  year: 2021
  ident: 2664_CR155
  publication-title: Leukemia
  doi: 10.1038/s41375-020-0810-4
– volume: 267
  start-page: 1
  year: 2017
  ident: 2664_CR118
  publication-title: Toxicol Lett
  doi: 10.1016/j.toxlet.2016.12.010
– volume: 23
  start-page: 7301
  issue: 23
  year: 2017
  ident: 2664_CR165
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.Ccr-17-1121
– volume: 151
  start-page: 16
  year: 2015
  ident: 2664_CR98
  publication-title: Pharmacol Ther
  doi: 10.1016/j.pharmthera.2015.02.004
– volume: 8
  start-page: 1156
  issue: 9
  year: 2018
  ident: 2664_CR166
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.Cd-17-1033
– ident: 2664_CR135
  doi: 10.1158/2159-8290.Cd-nb2016-164
– volume: 22
  start-page: 1347
  issue: 11
  year: 2017
  ident: 2664_CR156
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2017-0229
– volume: 80
  start-page: 5257
  issue: 23
  year: 2020
  ident: 2664_CR61
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.Can-19-3188
– volume: 25
  start-page: 3921
  issue: 13
  year: 2019
  ident: 2664_CR162
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.Ccr-18-2752
– volume: 4
  start-page: 1093
  issue: 11
  year: 2003
  ident: 2664_CR18
  publication-title: Nat Immunol
  doi: 10.1038/ni987
– volume: 99
  start-page: 12293
  issue: 19
  year: 2002
  ident: 2664_CR25
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.192461099
– volume: 4
  start-page: e601
  issue: 4
  year: 2013
  ident: 2664_CR119
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2013.131
– volume: 17
  start-page: 2596
  issue: 10
  year: 2016
  ident: 2664_CR95
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2016.11.010
– volume: 108
  start-page: 81
  issue: 1
  year: 2020
  ident: 2664_CR172
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2020.01.030
– volume: 70
  start-page: 2247
  issue: 8
  year: 2021
  ident: 2664_CR67
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-021-02862-2
– volume: 7
  start-page: 13587
  issue: 12
  year: 2016
  ident: 2664_CR145
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.7277
– volume: 64
  start-page: 5838
  issue: 9
  year: 2021
  ident: 2664_CR129
  publication-title: J Med Chem
  doi: 10.1021/acs.jmedchem.1c00017
– volume: 155
  start-page: 806
  year: 2018
  ident: 2664_CR131
  publication-title: Eur J Med Chem
  doi: 10.1016/j.ejmech.2018.06.041
– volume: 34
  start-page: 987
  issue: 2
  year: 2015
  ident: 2664_CR42
  publication-title: Oncol Rep
  doi: 10.3892/or.2015.4053
– volume: 78
  start-page: 855
  issue: 5
  year: 2010
  ident: 2664_CR123
  publication-title: Mol Pharmacol
  doi: 10.1124/mol.110.065961
– volume: 124
  start-page: 269
  issue: 3215
  year: 1956
  ident: 2664_CR6
  publication-title: Science
  doi: 10.1126/science.124.3215.269
– volume: 91
  start-page: 1261
  issue: 3
  year: 2017
  ident: 2664_CR116
  publication-title: Arch Toxicol
  doi: 10.1007/s00204-016-1784-x
– volume: 139
  start-page: 428
  issue: 4
  year: 2013
  ident: 2664_CR77
  publication-title: Immunology
  doi: 10.1111/imm.12099
– volume: 119
  start-page: 296
  issue: 4–5
  year: 2011
  ident: 2664_CR40
  publication-title: Apmis
  doi: 10.1111/j.1600-0463.2011.02733.x
– volume: 79
  start-page: 1369
  issue: 7
  year: 2019
  ident: 2664_CR63
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.Can-18-2558
– volume: 11
  start-page: 535
  issue: 9
  year: 2015
  ident: 2664_CR8
  publication-title: Nat Rev Endocrinol
  doi: 10.1038/nrendo.2015.117
– volume: 349
  start-page: 353
  issue: 1
  year: 2006
  ident: 2664_CR88
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2006.08.066
– volume: 17
  start-page: 2633
  issue: 12
  year: 2018
  ident: 2664_CR181
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.Mct-18-0643
– volume: 16
  start-page: 415
  issue: 5
  year: 2019
  ident: 2664_CR26
  publication-title: Cell Mol Immunol
  doi: 10.1038/s41423-019-0224-2
– volume: 79
  start-page: 311
  issue: 2
  year: 2019
  ident: 2664_CR147
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.Can-18-1003
– volume: 10
  start-page: 1187.DOI
  year: 2019
  ident: 2664_CR90
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2019.01187
– volume: 375
  start-page: 1319
  issue: 14
  year: 2016
  ident: 2664_CR158
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1607751
– volume: 20
  start-page: 4574
  issue: 17
  year: 2014
  ident: 2664_CR160
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.Ccr-14-0695
– volume: 23
  start-page: 4290
  issue: 15
  year: 2017
  ident: 2664_CR93
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.Ccr-16-3192
– volume: 184
  start-page: 114359.DOI
  year: 2021
  ident: 2664_CR148
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2020.114359
– volume: 30
  start-page: 399
  issue: 2
  year: 2016
  ident: 2664_CR161
  publication-title: Leukemia
  doi: 10.1038/leu.2015.240
– volume: 434
  start-page: 917
  issue: 7035
  year: 2005
  ident: 2664_CR144
  publication-title: Nature
  doi: 10.1038/nature03445
– volume: 6
  start-page: 25602
  issue: 28
  year: 2015
  ident: 2664_CR168
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.4693
– volume: 58
  start-page: 288
  issue: 2
  year: 2017
  ident: 2664_CR171
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.116.177584
– volume: 108
  start-page: 770
  year: 2017
  ident: 2664_CR79
  publication-title: Free Radic Biol Med
  doi: 10.1016/j.freeradbiomed.2017.04.018
– volume: 39
  start-page: 2835
  issue: 13
  year: 2020
  ident: 2664_CR85
  publication-title: Oncogene
  doi: 10.1038/s41388-020-1175-x
– volume: 289
  start-page: 34189
  issue: 49
  year: 2014
  ident: 2664_CR41
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M114.594721
– volume: 2
  start-page: 409
  issue: 5
  year: 2009
  ident: 2664_CR114
  publication-title: Cancer Prev Res (Phila)
  doi: 10.1158/1940-6207.Capr-08-0160
– volume: 15
  start-page: 1207
  issue: 11
  year: 2014
  ident: 2664_CR153
  publication-title: Lancet Oncol
  doi: 10.1016/s1470-2045(14)70391-2
SSID ssj0017860
Score 2.3619115
SecondaryResourceType review_article
Snippet Nicotinamide adenine dinucleotide (NAD) is the core of cellular energy metabolism. NAMPT, Sirtuins, PARP, CD38, and other molecules in this classic metabolic...
Abstract Nicotinamide adenine dinucleotide (NAD) is the core of cellular energy metabolism. NAMPT, Sirtuins, PARP, CD38, and other molecules in this classic...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1
SubjectTerms Adenosine
Angiogenesis
Antigens
Apoptosis
Breast cancer
CD38 antigen
Cell growth
Chemokines
Cytokines
Cytotoxicity
Drug delivery
Drug development
Drug discovery
Drug resistance
Energy metabolism
Enzymes
Hypoxia
Immunosuppressive agents
Immunotherapy
Ligands
Lymphocytes
Metabolic pathways
Metabolism
Metastasis
Microenvironments
NAD
NAD + metabolism
Neoantigens
Neutrophils
Review
Sirtuins
Tumor immune microenvironment
Tumor necrosis factor-TNF
Tumor therapy
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1JSywxEA4iCF7kueE8FyJ4k8buztLJ0RUR9KTgLWSpxsE3PTIL4r-3ku4Zpi_Pi4e-ZIF0pZKqIlXfR8gZXoqSAYPM5Q4DFF_yTAcnsshsjWGzLQKkbIsnef_CH17F6wrVV8wJa-GBW8FdQHCKi8Ch1IFXMncQtMqF07JmQtYpWkebtwimuveDSsl8USKj5MU0WrVYiVziJyXPip4ZSmj9PReznyC5YnHu_pCtzlWkl-0St8kaNDtkoyWP_Nol748Qq3aH0xHtEHveqG0CXaaO05R7hTcZHdf06fKGRvbhT_tFU_0KBDpqqXFhSocNnc1H4wkdxnIRoKOYprdSA7dHXu5un6_vs446IfOi4rOskJWPDL5gZS2hBu2YQ1fNS6cKr7y1lbVKuQq9lTwUgE6g9wK8dSwwYTFq3SfrzbiBA0IZY0IXrFYuIRnWTjAN2vMc9yHg9AEpFpI0vsMVj_QW_0yKL5Q0rfQNSt8k6ZtiQM6Xcz5aVI3_jr6KG7QcGRGxUwPqien0xPykJwNytNhe0x3TqSkrvMMU42U5IKfLbjxg8dXENjCe45gIH4RBlcJ1VD216C2o39MM3xJUt2ZMSS7__sYfHJLNMmkwWoX8iKzPJnM4Ro9o5k6S8n8DzQAKXA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkL4ikWCjISNxQ1iR-xT6g8qgqJnqi0N8uPCV3BJu1mV1X_fceONzSXHnJJbMUaj8cz9sz3EfIJjaJkwKBwpcMAxde80MGJIjJbY9hsqwAp2-JMnp7zn0uxzAduQ06r3NvEZKhD7-MZ-VHdoLopxuv6y-VVEVmj4u1qptB4SB5F6LKY0tUsp4CrapQs94UySh4NcW-L9cg1PlLyopptRgmzf-ZoztMk7-w7J8_I0-ww0uNxhp-TB9C9II9HCsmbl-TvL4i1u6thTTNuzwW1XaBTAjlNGVhoz2jf0rPj7zRyEF_bG5qqWCDQ9UiQCwNddXS7W_cbuopFI0DXMVnvTiXcK3J-8uP3t9MiEygUXjR8W1Sy8ZHHF6xsJbSgHXPosHnpVOWVt7axVinXoM9ShgrQFfRegLeOBSYsxq6vyUHXd_CGUMaY0BVrlUt4hq0TTIP2vAxaBey-INVeksZndPFIcvHPpChDSTNK36D0TZK-qRbk89TncsTWuLf11zhBU8uIi51e9Js_Ji8zA8EpLgKHWgfeyNIBjq8UTsuWCdniMA_302vyYh3Mf9VakI_TZ1xm8e7EdtDvsE0EEcLQSuE4mplazAY0_9KtLhJgt2ZMSS7f3v_zd-RJnXQTrX55SA62mx28R49n6z4ktb4F87UBjQ
  priority: 102
  providerName: ProQuest
Title Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment
URI https://www.proquest.com/docview/2704083422
https://www.proquest.com/docview/2696858581
https://pubmed.ncbi.nlm.nih.gov/PMC9338646
https://doaj.org/article/edb845d4e29d4760bed9805b96f356f0
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9RAEF9qi9IX8RNP67GCbxJNsp95EOlpSxF6SPHg8CXsx6Q97CV6H-j9985ucmcDxQcfkofsLiw7Ozsz2Znfj5DXeChKBgwSm1oMUFzOk8JbkQRmawybTeYhZluM5dmEf56K6R7Z0h11C7i8NbQLfFKTxfXb3z83H1Dh30eF1_LdMtisUGec4yMlTzAaOkDLpIKinvO_twpKy3RbOHPruENyj4kigKLnPTsV4fx7Pmg_g_KGSTp9QO53viQ9boX_kOxB_YjcbdklN4_J93MIZb2z5Zx2kD5X1NSe7nLLaUzOwqOONhUdH3-igZ74l9nQWOACns5b7lxY0llNV-t5s6CzUE8CdB7y-G4UyT0hk9OTrx_Pko5bIXFC8VWSSeUCxS8YWUmooLDMoi_npNWZ084YZYzWVqE7k_oM0Et0ToAzlnkmDIa1T8l-3dTwjFDGcM0yVmkboQ4rK1gBheOpL7TH4QOSbVeydB3weOC_uC5jAKJl2QqiREGUURBlNiBvdmN-tLAb_-w9CgLa9QyQ2fFDs7gsOw0swVvNheeQF54rmVrA-aXCFrJiQlY4zaOteMvtNixzhYecZjzPB-TVrhk1MFyrmBqaNfYJ-EIYdWmch-pti96E-i317CpieReMacnl8_8e-YIc5nEHo61Ij8j-arGGl-gnreyQ3FFTNSQHo5Pxl4th_NswjAqB74vRtz_NAxal
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKVgguiKe6UMBIcEJRk9hxnANCLW21pe0KoVbqzfgxoSvYpOxD1f4pfiNjJ1maS2895JLYyWg8nkc8Mx8h71EpCgYMIhMbDFBsyqPCmSzyyNYYNuvEQci2GIvROf96kV1skL9dLYxPq-x0YlDUrrb-H_lOmqO4ScbT9PPVn8ijRvnT1Q5CoxGLY1hdY8g2_3S0j-v7IU0PD86-jKIWVSCyWc4XUSJy68FtQYtSQAmFYQa9GCuMTKy0WudaS2lyNOSxSwD9I2szsNowxzKNAR2-9x7Z5AxDmQHZ3DsYf_u-PrfIpYi70hwpdubemvoK6BQvIXiU9MxfQAnoubb9xMwblu7wMXnUuqh0t5GpJ2QDqqfkfgNauXpGfp2CrxaezKe07RR0SXXl6DplnYacL9SgtC7peHefetTja72ioW4GHJ02kLwwp5OKLpbTekYnvkwF6NSnB96ovXtOzu-EuS_IoKor2CKUMZYVCSulCR0US5OxAgrLY1dIh9OHJOk4qWzbz9zDavxWIa6RQjXcV8h9FbivkiH5uJ5z1XTzuHX0nl-g9UjfiTvcqGc_VbuxFTgjeeY4pIXjuYgNIH1xZgpRskyUSOZ2t7yqVQ9z9V-Yh-Td-jFubH9aoyuolzjGty3CYE4iHXlPLHoE9Z9Uk8vQIrxgTAouXt7-8bfkwejs9ESdHI2PX5GHaZBTtDnxNhksZkt4jf7WwrxphZySH3e9r_4B9PFBLg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mechanism+research+and+treatment+progress+of+NAD+pathway+related+molecules+in+tumor+immune+microenvironment&rft.jtitle=Cancer+cell+international&rft.au=Xu%2C+QinChen&rft.au=Liu%2C+Xiaoyan&rft.au=Mohseni%2C+Ghazal&rft.au=Hao%2C+Xiaodong&rft.date=2022-07-30&rft.pub=BioMed+Central&rft.eissn=1475-2867&rft.volume=22&rft_id=info:doi/10.1186%2Fs12935-022-02664-1&rft_id=info%3Apmid%2F35906622&rft.externalDocID=PMC9338646
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1475-2867&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1475-2867&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1475-2867&client=summon